Drug intelligence / Profile preview

리메모Q

Development stage: Unknown
Lead developer: Kolab
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**리메모Q** is a consumer probiotic brain-health supplement developed by **Kolab** in South Korea. Based on company materials, it is positioned as a chewable, sugar-free xylitol-containing product for people concerned about declining cognitive function, memory, concentration, and oral health. Kolab markets the product within its broader Re:Memo consumer line focused on dementia prevention and cognitive support. The exact probiotic strain composition and molecular targets have not been publicly disclosed in the provided sources, so its mechanism is best described as an orally administered probiotic or microbiome-oriented nutraceutical intended to support brain and oral health rather than as a pharmaceutical with a defined target-mediated mechanism.

Brand names: 리메모Q
Other names: 리메모Q-Kolab-probiotic

Beyond the preview

Go deeper on 리메모Q.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 리메모Q.

Explore the full profile